Scientific Reports · Nov 19, 2026
In silico screening of FDA-approved drugs for elimination of senescent cells via senescence-associated anti-apoptotic pathway inhibition
By Manni E
Senescent cells activate senescence-associated anti-apoptotic pathways to evade apoptosis, leading to irreversible cell cycle arrest. Here, an in silico screening strategy was used to identify FDA-approved drugs that cause senescent cells to lose their ability to evade apoptotic pathways by targeting senescence-associated anti-apoptotic pathway (SCAP)-related genes. Absorption, distribution, metabolism, and excretion (ADME) parameters (reduced to 80), StopTox filtering (reduced to 15), and ProTox 3.0 classification were used to screen over 1500 chemicals obtained from the ZINC database. Three compounds, ZINC000000057255, ZINC000096006009, and ZINC000001530803, were selected for further examination based on their favorable LD₅₀ values. ZINC000001530803 was predicted to be non-toxic across the computational toxicity endpoints evaluated in this study. Twelve overlapping candidate targets were identified by intersecting PharmMapper-predicted compound targets with GeneCards-derived SCAP-related genes. For protein–protein interaction (PPI) network analysis, these 12 overlapping targets were combined with BCL2, MCL1, and BCL2L1 as anti-apoptotic pathway anchors, resulting in a 15-node network in which EGFR and AKT1 emerged as key hub genes. ZINC000000057255 had the best docking score and electronic stability but it was predicted to be toxic to the eye. ZINC000001530803 demonstrated a favorable predicted ADMET profile and established robust hydrogen-bond interactions with significant residues of EGFR and AKT1. Overall, ZINC000001530803 shows promise as a lead candidate for SCAP inhibition and warrants further refinement and experimental verification.